Yeah its just a rebrand but they are getting close to US direct to consumer launch.
But the market awaits bigger fish. AZ sales estimates for FY19. And a hook up with a ridgy didge payer/insurer. Oh yeah and the release of AZs new product. That would be nice. If I wasnt a cynic, maybe they are saving some of these for a cap raising in the not too distant future...
On another matter, I find it curious that at the last conference call earlier this month, they were still sticking to the $5.7 - $7M revenue guidance for the FY ending 30 June. Given first half revenue was $2.6 million (I believe), where is the $3 to 4 million coming from in the second half? Another AZ R&D payment?
ADR Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
